Skip to content

DR. BORKELMANS

Active Private limited companyfounded 2012active for 14 yearsPutstraat 49, 3630 MaasmechelenKBO/BCE: BE 0844.079.548

Lifetime

14 annual accounts with figures on one time axis
peak of €263,224 in 2016
€119,844▲ 9.9%
peak of €132,632 in 2014
€49,253▲ 36.2%
peak of €536,867 in 2016
€257,271▲ 9.1%
€4,884▼ 73.7%
Board3 names since 2012
1 director
Documentsfilings and deeds
10-07-202621 days before the deadline
2025micro format
Result from €36,165 to €49,253Dividend €27,721Debts from €18,537 to €4,884Cash from €103,747 to €152,078

Key points

from the 2025 annual accounts

Equity

€257,271 from €536,867 in 2016

Equity fell by 52% in 9 years.

Liquidity

42.17 was 14.72 in 2024

Short-term debts fell from €10,093 to €4,884.

Filings

14 annual accounts since 2012
AprilJune31 JulyOctober201520202025

Six of the last ten came late. The 2019 accounts came in latest, 76 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,726 companies had the same profile as DR. BORKELMANS has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,726 companies, not a prediction for DR. BORKELMANS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 50 sharesdeed of 15-01-2018
  • 50 sharesdeed of 15-01-2018
  • 50 sharesdeed of 15-01-2018
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0844079548
resigns as manager reappointed as director · Director discharge: · General meeting of 10-06-2021 · Gazette deed
Demerger: Dr. Borkelmans splits off to Dr. Groffils, praktijk Thomasboslaan Founding capital of €339,118.76 · The capital rose from €18,600 to €536,867.49 · The capital fell from €536,867.49 to €197,748.73 · appointed as manager · General meeting of 15-12-2017 · Gazette deed
Demerger proposal: Dr. Borkelmans splits off to Dr. Groffils, praktijk Thomasboslaan afgekort Dr. Groffils appointed as company auditor · Partner: (geneesheer vennoot) · Partner: · Board meeting of 01-01-2017 · Gazette deed
All 29 events

Comparable companies

same main activity, similar in size and age
Company
DR. BORKELMANS Maasmechelen €262,155 €119,844 98.1% -
PEUSENS PETER HUISARTS Peer €297,237 €126,719 85.1% -
DOKTER M. TRESINIE Bredene €246,429 €115,804 93.6% -
DOKTER VANESSA KENNINCK Antwerp €273,955 €112,983 98.6% -
Dr. Pans-Lindekens Elke Linter €284,286 €115,323 88.4% -
Dr. Björn Ledegen Antwerp €251,956 €111,229 62.2% -
C-MEDI-T Wavre €248,739 €118,927 75.7% -

These companies have the same main activity as DR. BORKELMANS: general medical practice (NACE 86210). They are comparable in size and age: total assets between €246,000 and €297,000, founded between 2010 and 2012.

Official details

Source: KBO
Status
Active since 28-02-2012Normal situation
Activity
General medical practiceNACE 86210
Financial year end
31 December
Peppol
Reachable since 05-10-2025
Company details

Annual accounts 2025

≈ €220,000estimated
€262,155▲ 3.1%
Filing
Filed on 10-07-2026, 21 days before the end of the filing period
Financials

Insights on DR. BORKELMANS

DR. BORKELMANS files the micro format. That format states no turnover. The gross margin rose from €89,839 in 2012 to €119,844 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DR. BORKELMANS

What is the company number of DR. BORKELMANS?
The company number of DR. BORKELMANS is 0844.079.548. The VAT number is the same number with BE in front: BE 0844.079.548.
Where is DR. BORKELMANS based?
The registered office is at Putstraat 49, 3630 Maasmechelen.Company details
What does DR. BORKELMANS do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of DR. BORKELMANS?
DR. BORKELMANS is a private limited company (BV).
When was DR. BORKELMANS founded?
DR. BORKELMANS was founded on 28-02-2012.
Is DR. BORKELMANS still active?
Yes, DR. BORKELMANS is an active enterprise in the KBO register.
What is the turnover of DR. BORKELMANS?
The turnover in financial year 2025 is ≈ €220,000. This figure is estimated from the gross margin of €119,844 and 30 comparable companies (NACE 86210). It probably lies between €170,000 and €270,000.Financials
Is DR. BORKELMANS profitable?
In financial year 2025, DR. BORKELMANS made a profit of €49,253.
Where can I find the annual accounts of DR. BORKELMANS?
DR. BORKELMANS filed 14 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DR. BORKELMANS due?
DR. BORKELMANS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.